Nurix Therapeutics(NRIX)
BRISBANE, CABiotechnology
Focus: Nurix is a publicly traded oncology-focused biotech specializing in small molecules and protein degradation therapies, currently advancing a pipeline of early-stage programs with a Phase 3 partnership with Roche.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
29+25 this month
Hot — 31 jobs added in 30d
Net +25 (31 new, 6 removed). Aggressive expansion phase.
Should You Work at Nurix Therapeutics?
AI assessmentBest fit for early-career scientists and regulatory professionals willing to ride a high-risk growth story with near-term financing uncertainty.
Why Work Here
- Pioneer in protein degradation technology with cutting-edge modalities in a hot oncology space, offering technical differentiation for scientists.
- Public company with $77M revenue and Roche partnership de-risks Phase 3 execution and provides credibility for milestone-driven bonuses.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$77M
Pipeline & Clinical Trials
NX-5948
Healthy VolunteerClinical Trials (3)
NCT07516093Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Phase 3Help build intelligence for Nurix Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.